Recent Updates — GRTX

Galera Therapeutics, Inc. effected a 1-for-200 reverse stock split of its common stock on July 12, 2026, via an amendment to its Restated Certificate of Incorporation. The split resulted in a reduction of shares available under the company's 2019 Equity Incentive Plan and 2023 Employment Inducement Award Plan, as well as a proportionate reduction in shares issuable upon the exercise of outstanding warrants and stock options, with corresponding exercise price adjustments. No fractional shares were issued; instead, stockholders received cash in lieu of fractional shares based on the closing price on the OTCQB Market prior to the effective date. The company trades under the ticker symbol GRTXD on a split-adjusted basis as of July 13, 2026. Galera Therapeutics is a biotechnology company.

Galera Therapeutics, Inc. announced a 1-for-200 reverse stock split of its common stock, which is expected to become effective on July 12, 2026. The split will automatically convert every two hundred shares into one share and will also adjust the exercise prices of outstanding stock options and warrants. Galera Therapeutics, Inc. is a biotechnology company focused on developing medical cannabis-based therapies.